Lisa Dombro - Agilon Health Chief Experience and Innovation Officer
| AGL Stock | USD 2.69 0.13 4.61% |
Insider
Lisa Dombro is Chief Experience and Innovation Officer of agilon health since 2021.
| Age | 52 |
| Tenure | 3 years |
| Address | 6210 East US Highway 290, Austin, TX, United States, 78723 |
| Phone | 562 256 3800 |
| Web | https://www.agilonhealth.com |
Agilon Health Management Efficiency
The company has Return on Asset of (0.0695) % which means that on every $100 spent on assets, it lost $0.0695. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2785) %, meaning that it generated no profit with money invested by stockholders. Agilon Health's management efficiency ratios could be used to measure how well Agilon Health manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.14. The value of Return On Capital Employed is expected to slide to -0.32. Net Tangible Assets is expected to rise to about 1.1 B this year, although the value of Total Assets will most likely fall to about 1.3 B.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sue Schick | Humana Inc | N/A | |
| Kenneth Burdick | Centene Corp | 62 | |
| Michael Koeberlein | Humana Inc | 52 | |
| John Gallina | Elevance Health | 64 | |
| Scott Anglin | Elevance Health | N/A | |
| Esq JD | Molina Healthcare | 59 | |
| Dave Reynolds | Molina Healthcare | N/A | |
| Sarah London | Centene Corp | 43 | |
| Marcy Klevorn | Humana Inc | 61 | |
| JohnPaul Felter | Humana Inc | 41 | |
| David Thomas | Centene Corp | 58 | |
| Anil Bhatt | Elevance Health | N/A | |
| Leslie Norwalk | Centene Corp | 55 | |
| Jennifer Gilligan | Centene Corp | N/A | |
| W Dunbar | Humana Inc | 57 | |
| PharmD PharmD | Humana Inc | 54 | |
| Wayne DeVeydt | Centene Corp | 51 | |
| Carolyn Tandy | Humana Inc | N/A | |
| Colin Toney | Centene Corp | 35 | |
| Nwando Olayiwola | Humana Inc | N/A | |
| Susan Schick | Humana Inc | 58 | |
Management Performance
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.0695 |
agilon health Leadership Team
Elected by the shareholders, the Agilon Health's board of directors comprises two types of representatives: Agilon Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Agilon. The board's role is to monitor Agilon Health's management team and ensure that shareholders' interests are well served. Agilon Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Agilon Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Benjamin Shaker, Chief Officer | ||
| Girish Venkatachaliah, Chief Technology Officer | ||
| Bill Farry, Chief Innovation | ||
| Derek Strum, Director | ||
| Michelle Gourdine, Independent Director | ||
| Timothy Gertsch, Controller VP | ||
| Denise Zamore, Chief Secretary | ||
| Sharad Mansukani, Independent Director | ||
| Jeffrey CPA, Executive CFO | ||
| Michael Smith, Independent Director | ||
| William Wulf, Director | ||
| Mat Varghese, Chief Officer | ||
| Benjamin Kornitzer, Chief Medical and Quality Officer | ||
| Claire Mulhearn, Chief Officer | ||
| Ben Shaker, Chief Markets Officer | ||
| Joan Danieley, Chief Administrative Officer | ||
| Matthew CFA, Vice Relations | ||
| Lisa Ali, Chief Officer | ||
| Ronald Williams, Non-Executive Chairman of the Board | ||
| Lisa Dombro, Chief Experience and Innovation Officer | ||
| Ravi Sachdev, Vice Chairman of the Board | ||
| Karen Mcloughlin, Director | ||
| Priscilla Kasenchak, Chief Officer | ||
| Chris Casler, Chief Human Resource Officer | ||
| Timothy Bensley, Chief Financial Officer | ||
| Leland Thomas, Senior Relations | ||
| Clay Richards, Independent Director | ||
| Veeral Desai, Chief Strategy and Development Officer | ||
| Richard Schnall, Director | ||
| Steven Sell, President, Chief Executive Officer, Director | ||
| Theodore Halkias, Chief Business Officer |
Agilon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Agilon Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.0695 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | (0.03) % | ||||
| Current Valuation | 801.33 M | ||||
| Shares Outstanding | 411.48 M | ||||
| Shares Owned By Insiders | 1.78 % | ||||
| Shares Owned By Institutions | 98.22 % | ||||
| Number Of Shares Shorted | 36.49 M | ||||
| Price To Earning | 23.14 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in agilon health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Agilon Stock please use our How to buy in Agilon Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agilon Health. If investors know Agilon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agilon Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 11.951 | Earnings Share (0.54) | Revenue Per Share 12.953 | Quarterly Revenue Growth 0.387 | Return On Assets (0.07) |
The market value of agilon health is measured differently than its book value, which is the value of Agilon that is recorded on the company's balance sheet. Investors also form their own opinion of Agilon Health's value that differs from its market value or its book value, called intrinsic value, which is Agilon Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agilon Health's market value can be influenced by many factors that don't directly affect Agilon Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agilon Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agilon Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agilon Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.